text:
Graeme Swann: England will have to take early wickets for a whitewash
Spinner Graeme Swann believes England will have to take early wickets today if they are to complete a 4-0 series whitewash against India at the Oval.
Jimmy Anderson celebrates another wicket
After asking India to follow on, England managed three second-innings wickets as the tourists closed on 129 for three – still trailing by 162 runs.
Swann claimed two of the wickets to fall, including first-innings centurion Rahul Dravid, as his slow right-arm spin looked set to be crucial to England's hopes on a wearing final-day wicket.
After a summer when England's seamers have done most of the damage on conducive wickets, Swann admitted he was looking forward to finally getting his chance to play a key role.
"It excites me – especially after you play a whole season on belting batting and seaming wickets," he said.
"It is nice to get a spinning wicket. We need to make inroads in the morning. We've got 20 overs where the ball will talk a lot.
"It was easier once we got the hard ball. It died a bit early on.
"I was fairly happy with the way I bowled all day. My body is aching like it hasn't all summer, but it's a nice ache."
Dravid was disappointed to fall for 13 before the close last night after he batted through India's first innings to be unbeaten on 146.
Swann eked him out with a ball Dravid admitted had just nicked before being caught by Alastair Cook at short leg.
India's batting has relied upon his defiance in the series but Dravid believes star man Sachin Tendulkar – who reached stumps unbeaten on 35 – can finally find form today and save the tourists from a whitewash.
"It's been a tough series," he said. "They are a quality side and have bowled well as a group. Some of us have had a tough series, but hopefully today it is Sachin's day."


text:
DMS Newsroom Content
Digital Media Solutions Announces New $275 Million Senior Secured Credit Facility
CLEARWATER, Fla.–(BUSINESS WIRE)– Digital Media Solutions, Inc. (NYSE: DMS), a leading provider of technology-enabled digital performance advertising solutions connecting consumers and advertisers, today announced that its operating subsidiary, Digital Media Solutions, LLC, has entered into a new $275 million five-year senior secured credit facility, which consists of term loans in an aggregate principal amount of $225 million and a $50 million revolving credit facility.
Proceeds from the term loans were used to repay and terminate the previous $220 million senior secured credit facility, which consisted of term loans in an aggregate principal amount of $205 million and a $15 million revolving credit facility. At closing, the new revolver was undrawn.
In conjunction with the $275 million refinancing transaction, S&P Global Ratings assigned a 'B' Issuer Credit Rating and Moody's Investors Service assigned a 'B2' Corporate Family Rating to Digital Media Solutions, LLC.
The new credit facility provides increased borrowing capacity, a new five-year tenor and lower amortization, along with greater strategic and operational flexibility. The revolving facility can be used to finance working capital needs, permitted acquisitions and investment, capital expenditures, and general corporate purposes.
"This new credit facility, with its increased capacity and extended maturity, is another important step in the financial transformation of Digital Media Solutions," said Joe Marinucci, Digital Media Solutions Chief Executive Officer. "It provides us with increased financial flexibility to support our key growth initiatives."
The new credit facility is governed by a maximum net leverage covenant of 5.00x, with a step down to 4.50x over time. Truist Securities, Inc. and Fifth Third Bank, National Association, acted as Joint Lead Arrangers and Joint Bookrunners for the financing. Truist Bank also serves as the Administrative Agent, Collateral Agent, a Lender and an Issuing Bank.
This press release includes "forward-looking statements'' within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. DMS's actual results may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. These forward statements are often identified by words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions. These forward-looking statements include, without limitation, DMS's expectations with respect to its future performance and its ability to implement its strategy, and are based on the beliefs and expectations of our management team from the information available at the time such statements are made. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside DMS's control and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the COVID-19 pandemic or other public health crises; (2) changes in client demand for our services and our ability to adapt to such changes; (3) the entry of new competitors in the market; (4) the ability to maintain and attract consumers and advertisers in the face of changing economic or competitive conditions; (5) the ability to maintain, grow and protect the data DMS obtains from consumers and advertisers; (6) the performance of DMS's technology infrastructure; (7) the ability to protect DMS's intellectual property rights; (8) the ability to successfully source and complete acquisitions and to integrate the operations of companies DMS acquires; (9) the ability to improve and maintain adequate internal controls over financial and management systems, and remediate the identified material weakness; (10) changes in applicable laws or regulations and the ability to maintain compliance; (11) our substantial levels of indebtedness; (12) volatility in the trading price on NYSE of our common stock and warrants; (13) fluctuations in value of our private placement warrants; and (14) other risks and uncertainties indicated from time to time in DMS's filings with the SEC, including those under "Risk Factors'' in DMS's Annual Report on Form 10-K and its subsequent filings with the SEC. There may be additional risks that we consider immaterial or which are unknown, and it is not possible to predict or identify all such risks. DMS cautions that the foregoing list of factors is not exclusive. DMS cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. DMS does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.
About Digital Media Solutions
Digital Media Solutions, Inc. (NYSE: DMS) is a leading provider of technology-enabled digital performance advertising solutions connecting consumers and advertisers within auto, home, health and life insurance plus a long list of top consumer verticals. The DMS first-party data asset, proprietary advertising technology, significant proprietary media distribution and data-driven processes help digital advertising clients de-risk their advertising spend while scaling their customer bases. Learn more at
https://digitalmediasolutions.com
Melissa Ledesma
mledesma@dmsgroup.com
press@dmsgroup.com
Source: Digital Media Solutions, Inc.
Digital Media Solutions Set To Join Russell 3000® Index
Digital Media Solutions has been selected to join the broad-market Russell 3000® Index at the conclusion of the 2021 Russell indexes annual reconstitution.
Digital Media Solutions To Participate In Upcoming Virtual Investor Conferences
Digital Media Solutions to participate in Craig-Hallum's, Stifel's, and Canaccord's upcoming virtual investor conferences.
Jared Klein, DMS VP of Advertiser Partnerships, In mThink: Top 4 Best Practices For Consumer Finance Campaigns
In the thought leadership piece, Klein outlines four top best practices for consumer finance campaigns.
DMS Secures #1 Spot As Top CPA Network for Affiliates & Publishers 2023
DMS announced its No. 1 spot on the mThink "Top CPA Networks for Affiliates & Publishers List" 2023.
Digital Media Solutions, Inc. Announces Q3 2022 Financial Results
DMS announces Q3 2022 financial results.
Scott Vogel, DMS VP Of Health Insurance, In mThink: 3 Strategies To Optimize Your OEP/AEP Campaign Strategy
The mThink website featured an article authored by DMS Vice President of Health Insurance Scott Vogel, titled "3 Strategies To Optimize Your OEP/AEP Campaign Strategy."
DMS Receives Non-Binding "Go Private" Proposal
DMS today announced that its board of directors has received an offer from Prism Data, LLC.
DMS Announces Q2 2022 Financial Results
DMS and Seekr Announce New Strategic Partnership
Seekr will leverage the power of the DMS toolset to maximize advertising results and scale its global user reach.
DMS Announces Second-Quarter Fiscal 2022 Earnings Release Date, Conference Call And Webcast
DMS will release its second-quarter results after the U.S. stock market closes on Tuesday, August 9, 2022 and will hold a conference call to discuss results at 5:00 p.m. (Eastern Time) that day.
Digital Media Solutions to Participate in Upcoming Canaccord Genuity 42nd Annual Growth Conference Next Month
DMS will present at the Canaccord Genuity 42nd Annual Growth Conference at the InterContinental Boston located in Boston, Massachusetts on Thursday, August 11 at 10:00 am ET.
DMS Announces CFO Transition
Company Names Financial Leader Richard Rodick As Chief Financial Officer
DMS Names Insurance Industry Leader Billy Hubbard SVP Of Strategic Accounts
DMS announced that insurance marketing leader Billy Hubbard has been named Senior Vice President of Strategic Accounts.
DMS Announces the Acquisition of Traverse Data, Inc. & Enhancements to Its Data Program & Technology Stack
Digital Media Solutions announces the acquisition of Traverse Data, Inc. & enhancements to its data program & technology stack.
DMS Announces Q1 2022 Financial Results and Enhances Technology Stack and Data Asset
Jason Rudolph Talks Audience Intelligence In PerformanceIn
PerformanceIN published an executive thought leadership piece by DMS CTO, Jason "JR" Rudolph titled, "How Audience Intelligence and Data-Driven Marketing Drives Superior Results."
DMS Announces Unique Publisher Contest & The Chance To Win The Trip Of A Lifetime
The Carpe Oportunidad contest began on April 7 and will award four DMS publishers with trips to Barcelona, Spain and tickets to Affiliate World Europe.
Rob Camhe Talks Power Of Performance Marketing With PerformanceIN
PerformanceIN published an executive thought leadership piece by Rob Camhe, DMS SVP of Strategic Partnerships, titled "Generating High-Quality, High-Converting Leads with Performance Marketing."
DMS Announces First-Quarter Fiscal 2022 Earnings Release Date, Conference Call And Webcast
DMS will release its first-quarter results after the U.S. stock market closes on Tuesday, May 10, 2022 and will hold a conference call to discuss results at 5:00 p.m. (Eastern Time) that day.
DMS Announces Participation In Noble Capital Markets' 18th Annual Investor Conference
DMS announced that the company will present at the Noble Capital Markets' Eighteenth Annual Investor Conference at the Hard Rock Hotel & Casino located in Hollywood, Florida on Thursday, April 21.
DMS Leaders Spotlight The Impact Of A Diverse Workforce At LeadsCon 2022
Kathy Bryan & Gaby Henriquez will share how empathy helps marketers boost LTV for campaigns during an insightful thought leadership session.
Digital Media Solutions, Inc. Announces Q4 and Full Year 2021 Financial Results
DMS announces Q4 and full year 2021 financial results.

redpajama_set_name: RedPajamaCommonCrawl


text:
Kanye West Says…
Kanye West Says He Wants to Run for President in 2024 and Reveals He Might Change His Name
Kanye West has announced his plans to run for president in 2024 — but before potentially moving into the White House the rapper might change his name.
Speaking at Fast Company's Innovation Festival, West, 42, was joined on stage by his Yeezy collaborator Steven Smith.
I'm learning beat production, I want to be like DJ Khaled- DJ Switch
"When people say it's crass to call yourself a billionaire, I say I might legally change my name to Christian Genius Billionaire Kanye West for a year until y'all understand exactly what it is," he said. "It will be on the license plate."
That's when West shifted the conversation to his plan to run for president.
"When I run for president in 2024 —" West said, to laughter from the audience. "What y'all laughing at?"
West said that if he were elected president, he would "create so many jobs."
"I'm not going to run, I'm going to walk," he said. "What they're saying is Kanye's crazy — one and three African Americans are in jail and all the celebrities are in jail also because they can't say nothing because they're so scared."
Drake ventures into the booming Marijuana industry
West also said he believes African American voters are treated as a "demographic" alone, something he said he has experienced as an African American fashion designer.
"As black designers out of America, you can't have an opinion," he said. "You can only be the consumer… you can only be a demographic."
"And that a boardroom says 'this is the black demographic…This is who you're supposed to vote on," he continued. "This is what you're supposed to buy. This is your Popeye's chicken sandwich you're supposed to eat on. I have seen the boardroom and back. And it's completely the concept of a demographic."
The conversation later turned from politics to innovations that West is making as a designer.
The "God Is" singer said that Yeezy is set apart from other brands in part because he doesn't follow the typical cycles of the fashion industry.
"We don't put a timeline on things," West said. "The idea of competition that's out there helps present a timeline. It makes things be better. Forces as creatives to bring things to market because Yeezy is the Apple of apparel. There hasn't been an Apple of apparel —there hasn't been that thing."
West also revealed that he plans for the new Yeezy sneaker to be made partly out of algae and that he is moving the company's headquarters to Cody, Wyoming.
The kitchen is my office, I don't like men cooking for me-Nana Aba Anamoah
"We have 4,000 acre ranch and a couple of other properties out there," the father of four said. "We're going to be farming and going seed to sow and have our own cotton, hydroponic farm, hemp farm, and wheat farm… and getting into how we can have last impact with the dyes because our colors are a big signature of the brand."
West also said that the company is aiming to be more "responsible."
"So dyeing is one of the main things that's impacting the planet in the fashion industry so just being responsible from A to Z," he said. "Our goal within the next two years is to bring the manufacturing back to America, South America, and North America and bring it back stateside and also present jobs for people back here.
Source: People.com
Lydia Forson Writes: The Politics of promises, deceit and a starving country


text:
Troubled Teenagers
"Where do my children go at night?" wails the distraught but passive mother in a powerful film called "River's Edge." She doesn't know and doesn't try to find out. Such parental neglect may be one reason for the plight of the film's unfeeling teenagers. Learning that one of them has slain another, they decide not to report the crime but to protect the killer.
"They have to make up their own moral codes in the absence of an inherited moral code," says Neal Jimenez, the screenplay's author. "They're not getting it from teachers or parents or society." The film was based loosely on a real case in which a 16-year-old boy killed his 14-year-old girlfriend in 1981 in Milpitas, Calif., a community near San Jose. The boy bragged about the killing to his friends and took nearly a dozen of them to see the body. For two days, no one called the police.
Unlike most movies with teenage protagonists, "River's Edge" challenges, rather than celebrates, youth and its culture. To the surprise of many in the movie business the film is proving a success at the box office. In fact it may he part of a larger trend, an apparent new willingness to recognize that many teenagers, white and black, affluent and poor, are in a bad way these days—neglected by their parents and growing up under the powerful influence of peer pressures, television, rock music and an exploitative youth culture.
Juveniles and the Justice System
Sep. 11, 2015 Reforming Juvenile Justice
Mar. 05, 2010 Youth Violence
Nov. 07, 2008 Juvenile Justice
Apr. 27, 2001 Kids in Prison
Mar. 15, 1996 Preventing Juvenile Crime
Feb. 25, 1994 Juvenile Justice
Jul. 17, 1987 Troubled Teenagers
Jul. 27, 1979 Juvenile Justice
Feb. 11, 1970 Juvenile Offenders
Jul. 17, 1957 Reform of Delinquents
Sep. 25, 1953 Youngsters in Trouble
Sep. 08, 1950 Teen-Age Lawbreakers
Feb. 23, 1943 Juvenile Delinquency


text:
Chomarat Receives JEC Innovation Award As Partner in the Fast RTM Project
Submitted on Wed 22 Feb 2017
The Fast RTM project is sponsored by the IRT M2P technology research institute and brings in manufacturers, universities and technical centres. The result is a flexible project that can be adapted to the requirements of builders in the automotive, aerospace and railway industries.
Philippe Sanial, R&D Director at Chomarat said; "This collaborative approach corresponds perfectly to Chomarat's innovation strategy. We are very proud to be a stakeholder in this project, and we would like to congratulate all of our partners for this award, which represents a real honour in the profession."
The Fast RTM project demonstrates the feasibility of using reactive RTM processes in the high-volume production of structural automotive parts. Under this project, CHOMARAT has developed optimised reinforcements that are compatible with the thermoplastic and thermoset resins used on the platform. The reinforcements are preformable, and suitable for high-speed processes and for the Fast RTM industrial platform. Entirely automated, the platform makes use of the compression resin transfer moulding (C-RTM) process.
Chomarat and the partners of the project receives the JEC Innovation Award 2017: Process.
The other partners of the project are: Partners: Arkema (France), Compose (France), Composite Integrity by Institut de Soudure Groupe – Composite Platform (France), Faurecia (France), Hexion (France), Hutchinson (France), PINETTE P.E.I. (France), Renault (France), SISE (France)
Website: www.chomarat.com
Chomarat
JEC Award


text:
Laal Singh Chaddha POSTPONED & Gets A New Release Date; Aamir Khan Lands In Turkey To Resume The Shoot
A picture of him on an international airport in the foreign country has been going viral.
The shooting for Aamir Khan's next titled Laal Singh Chaddha, was going on smoothly as per the deadline until the pandemic hit the shores. Just like many other big projects, the film has also suffered the wrath of COVID-19, and as per the latest update has been postponed for a year.
Yes, you read that right, even our heart is broken. Laal Singh Chaddha starring Aamir Khan and Kareena Kapoor Khan will now release on Christmas 2021. A year late than the actual release date, which was Christmas 2020. The reshuffling is the effect due to the delay in schedules.
In other news, Aamir Khan has reportedly landed in Turkey to resume the shoot for Laal Singh Chaddha. A picture of him on an international airport in the foreign country has been going viral. As per reports, it is almost confirmed that the actor is there to start work. Though there is no confirmation on whether Kareena Kapoor Khan and the rest of the cast will join him or not.
7 Years Of Chennai Express: Here Are 7 Box Office Facts About Shah Rukh Khan & Deepika Padukone's Rom-Com That You Will Totally Love
Disha Salian's Last Phone Call Was To A Friend, Not Sushant Singh Rajput!
Meanwhile, for the ones unaware, Laal Singh Chaddha is the official remake of the Oscar-Winning Hollywood classic Forrest Gump. The original starred Tom Hanks and is till date a favourite amid masses. The Hindi remake is being helmed by Secret Superstar fame Advait Chandan.
Alongside Aamir Khan and Kareena Kapoor Khan, Laal Singh Chaddha also stars Mona Singh, Manav Vij and South superstar Vijay Sethupathi in pivotal parts. The team has already shot for a major chunk in different parts of India.
How excited are you for the film? Let us know in the comments section below.
Manav Vij
Mona Singh
Vijay Sethupathi
Ameesha Patel Finally Breaks Silence On Her Feud Rumours With Kareena Kapoor Khan, Says "She Has Opinions, Ler Her Be Entitled To Them"
Ed Sheeran & Doja Cat To Bring Alive Brit Awards 2022...
Camila Cabello Visits A S*x Shop After Being Spotted With Ex...
Bachchan Pandey: Akshay Kumar Starrer Received A Record-Breaking 'Direct To OTT'...
Jacqueline Fernandez Shares First Insta Post After Weeks Amid Conman Sukesh...
When 'Spider-Man' Tom Holland Was Punched In The Face Cracking His...
Actor-MP Amol Kolhe Playing Nathuram Godse In 'Why I Killed Godse'...
Malaika Arora's Metallic Wardrobe Is A Mashup Of 'Shiny & S*xy'...


text:
Franc Kramberger (* 7. Oktober 1936 in Sveti Lenart v Slovenskih goricah, deutsch St. Leonhard in den Windischen Büheln) ist emeritierter Erzbischof von Maribor.

Franc Kramberger wurde am 29. Juni 1960 in der Kathedrale St. Johannes des Täufers (Dom zu Maribor) zum Priester geweiht. 1965 wurde er Präfekt des Slomšek-Studentenseminars in Maribor und war dort bis 1972 als Leiter tätig. Ab 1974 unterrichtete er an der Theologischen Fakultät in Ljubljana (Laibach).

Am 6. November 1980 wurde er von Papst Johannes Paul II. zum Bischof von Maribor ernannt. Die Bischofsweihe spendete ihm am 21. Dezember 1980 der Apostolische Nuntius in Jugoslawien Erzbischof Michele Cecchini; Mitkonsekratoren waren der Erzbischof von Ljubljana Alojzij Šuštar und der Bischof von Graz-Seckau Johann Weber. Am 7. April 2006 wurde die Diözese Maribor zur Erzdiözese erhoben und Kramberger war der erste Erzbischof von Maribor. Durch die Neugründung der Maribor unterstehenden Diözesen Murska Sobota und Celje wurde Kramberger auch Metropolit.

Erzbischof Kramberger stand aufgrund riskanter wirtschaftlicher Aktivitäten seiner Erzdiözese in den Jahren 2007 und 2011 in der Kritik. Deshalb ernannte Papst Benedikt XVI. am 31. Januar 2009 den früheren Weihbischof (2000–2006) Anton Stres zum Koadjutorbischof von Maribor. Am 3. Februar 2011 nahm der Papst seinen Amtsverzicht kurz vor Erreichen der Altersgrenze von 75 Jahren an.

2018 wurde Kramberger wegen Untreue im Rahmen der genannten Aktiengeschäfte von der slowenischen Staatsanwaltschaft angeklagt. Kramberger, neben dem der ehemalige Diözesanökonom Mirko Krašovec und zwei weitere Männer angeklagt wurden, bestritt eine direkte Tatbeteiligung. Der erste Gerichtstermin wurde für den 5. April 2018 anberaumt.

Literatur

 Folgenschwere Insolvenz, ORF.at, 22. Januar 2011

Einzelnachweise

Römisch-katholischer Bischof (20. Jahrhundert)
Römisch-katholischer Bischof (21. Jahrhundert)
Erzbistum Maribor
Person des Christentums (Slowenien)
Slowene
Geboren 1936
Mann

redpajama_set_name: RedPajamaWikipedia


text:
Q: DirectX 11.1 Disable the depth buffer This question relates to a previous question I have asked.
I have a series of 48 textures on flat square meshes that I am rendering and they all combine to form one "scene."  They each have a large percentage of of transparency with one or two smaller images, and when they are line up, I should be able to see the full scene.  I expected this would work without much issue, but when when I went to test it, I see the top-most texture, and then anywhere it would have transparency, it is just the clear color.
At first, I thought it was an issue with how I was loading the image and somehow was disabling the alpha, but after playing around with the clear color, I realized that there was some transparency.
Second, I tried was to enable blending - this works if all the textures get combined on a single z plane.
I have posted my image loading and blending code on the question I linked to above.
Now I am starting to think it may be an issue with the depth buffer, so I added the following code to my window dependent resources:
Microsoft::WRL::ComPtr<ID3D11DepthStencilState> DepthDefault;

D3D11_DEPTH_STENCIL_DESC depthstencilDesc;
ZeroMemory(&depthstencilDesc, sizeof(depthstencilDesc));
depthstencilDesc.DepthEnable = FALSE;
depthstencilDesc.DepthWriteMask = D3D11_DEPTH_WRITE_MASK_ALL;
depthstencilDesc.DepthFunc = D3D11_COMPARISON_ALWAYS;
depthstencilDesc.StencilEnable = FALSE;

depthstencilDesc.BackFace.StencilDepthFailOp = D3D11_STENCIL_OP_KEEP;
depthstencilDesc.BackFace.StencilFailOp = D3D11_STENCIL_OP_KEEP;
depthstencilDesc.BackFace.StencilFunc = D3D11_COMPARISON_ALWAYS;
depthstencilDesc.BackFace.StencilPassOp = D3D11_STENCIL_OP_KEEP;

depthstencilDesc.FrontFace.StencilDepthFailOp = D3D11_STENCIL_OP_KEEP;
depthstencilDesc.FrontFace.StencilFailOp = D3D11_STENCIL_OP_KEEP;
depthstencilDesc.FrontFace.StencilFunc = D3D11_COMPARISON_ALWAYS;
depthstencilDesc.FrontFace.StencilPassOp = D3D11_STENCIL_OP_KEEP;

DX::ThrowIfFailed( direct3d.device->CreateDepthStencilState(&depthstencilDesc, DepthDefault.GetAddressOf() ) );

direct3d.context->OMSetDepthStencilState(DepthDefault.Get(), 0);

Even with this code, I am only seeing the topmost layer.  Am I missing something, or am I setting something incorrectly?
Edit: To visualize the problem, it's as if I had 48 panes of glass that are all the same size and they are all in a row.  Each piece of glass has one image somewhere on it.  When you look through all the glass panes, you get one extra awesome image of all the smaller images combined.  For me, directx or the pixel shader is only drawing the first glass pane and filling all the transparency of the first pane with the clear/background color.
Edit: The code I'm using to create the depthstencilview:
CD3D11_TEXTURE2D_DESC depthStencilDesc( DXGI_FORMAT_D24_UNORM_S8_UINT, backBufferDesc.Width, backBufferDesc.Height, 1, 1, D3D11_BIND_DEPTH_STENCIL );

ComPtr<ID3D11Texture2D> depthStencil;
DX::ThrowIfFailed( direct3d.device->CreateTexture2D( &depthStencilDesc, nullptr, &depthStencil ) );

auto viewDesc = CD3D11_DEPTH_STENCIL_VIEW_DESC(D3D11_DSV_DIMENSION_TEXTURE2D);

DX::ThrowIfFailed( direct3d.device->CreateDepthStencilView( depthStencil.Get(), &viewDesc, &direct3d.depthStencil ) );

That code is literally right above my depth test/ D3D11_DEPTH_STENCIL_DESC code.  I'm presuming that this creates the depth code.

A: I think you might need to sort the order in which you render your vertices if you want to render semi-transparencies with a depth buffer. If you don't want to use a depth buffer - perhaps just don't define/create/set it?

redpajama_set_name: RedPajamaStackExchange


View Flour Grinding Mill 950mm, details & specifications from Sharad Enterprises, a leading Manufacturer of Flour Mill Machine in Dev Nagar, Jodhpur, Rajasthan. Get contact details, address, map on IndiaMART.
Manufacturer of Diamant type Mills fitted with Millstones - Vertical Flour Grinding Mill (Diamant type) offered by Sukhsa Exports, India, Jaipur, Rajasthan. ... Engsko Type Horizontal Millstone.
Alibaba.com offers 325 millstone machine products. About 16% of these are flour mill, 11% are other food processing machinery, and 1% are coffee makers. A wide variety of millstone machine options are available to you, such as grain processing equipment, espresso coffee maker, and floor polisher.
750g Electric Herb Grain Grinder Cereal Wheat Powder Flour Mill Grinding Machine (7) 4.3 out of 5 stars. AU $26.31 New. 220v Automatic Desk-top Continuous Hammer Mill Herb Grinder Pulverizer Df-15 (1) 5 out of 5 stars. ... Create delicious dishes with a food grinder. Food grinders are something that surely no Australian can do without.
Sharad Enterprises - offering Grinding Machine, Aata Mill Machine, Atta Chakki Machine, Atta Mill Machine, Flour Milling Equipment, Maida Mill Machinery at Rs 25000 /unit in Jodhpur, Rajasthan. Get best price and read about company and get contact details and address.


text:
Home Renewables Biomass Year-old biomass gas process may be more efficient than expected
On Site Renewables
Year-old biomass gas process may be more efficient than expected
ATLANTA, Ga., Aug. 1, 2001 à'– A year-old biomass gasification process developed by Atlanta-based Future Energy Resources Corp. (FERCO) to help utilities meet their renewable energy requirements has been found to be even more efficient than first anticipated.
For competitive energy companies, the findings reported from the McNeil Generating Plant test site in Burlington, VT, could be an important breakthrough, reports the current issue of Energy Competition Strategy Report, published by Atlanta-based NHI Publications.
FERCO's proprietary gasification process uses solid fuels, such as wood chips, municipal solid waste, and switch grass. The company converts the resulting biomass into a natural gas-like substance, called SilvaGas, which can be used as a direct substitute for natural gas. The FERCO process can convert biomass into electric power at twice the efficiency of conventional biomass systems.
SilvaGas also is said to significantly reduce carbon dioxide emissions, compared to fossil fuel-based power plants.
According to industry experts, the process is likely to win acceptance among energy providers seeking to achieve renewable energy goals and for those coping with fluctuating natural gas prices. The cost of the SilvaGas now ranges from $3 to $3.50 per million BTU, and natural gas is trading between $3.50 and $5 per million BTU, according to FERCO's CEO Inge Freitheim. "That puts us in an interesting competitive position," Freitheim says.
The FERCO executive says along with its competitive pricing the biomass gasification process is versatile and responsive, qualities important for its future integration into distributed generation systems, such as microturbines or fuel cells.
Other highlights of this month's Energy Competition Strategy Report include:
* Enterprise energy management, or demand response systems, combined with distributed generation systems can ease the nation's energy supply and reliability, according to one Canadian energy company.
* Analyses of Northeast wholesale markets and U.S. regional transmission organizations reveal market flaws, barriers, and difficulties. ECSR explores what these problems portend for restructuring.
* The Texas pilot program, Texas Electric Choice, opened June 1, and many utilities and energy service providers had to accomplish considerable systems integration work to get ready for it. Middleware, tagged a "digital nervous system," helped one of those companies, TXU, prepare for the launch.
* As companies streamline operations and cut costs to remain competitive, experts warn not to cut their Supervisory Control and Data Acquisition (SCADA) systems.
Free three-month trial subscriptions to Energy Competition Strategy Report are available by sending an e-mail with your full mailing address to nhi@nhionline.net or calling 800-597-6300.
Previous articleBrazil's toughest challenge
Next articleMirant to acquire EcoElectrica in Puerto Rico
Pressure on corporates to decarbonise drives demand for renewables
India and IRENA strengthen partnership on renewables and green hydrogen


Terence P. was shocked, SHOCKED! to find that this Portland, Maine Goodwill store was ClOSED.
Hi there! This is actually the Good Cause Thrift Shop, NOT Goodwill! None of our stores are closed! You can find our locations at www.goodwillnne.org.
hmmm interesting. i just noticed this now actually. care to exchange links?


text:
Delphinium austriacum är en ranunkelväxtart. Delphinium austriacum ingår i släktet storriddarsporrar, och familjen ranunkelväxter.

Underarter

Arten delas in i följande underarter:

 D. a. austriacum
 D. a. drescheri
 D. a. stiriacum

Källor

Storriddarsporrar
austriacum


Is 14 February your worst day of the year? Do we have some cars for you!
Not everyone has a significant other on the most romantic day of the year. But who needs someone else, anyway? If you want to be alone, here are the cars for you.
The clue is in the name. The BAC Mono is designed for one person, and one person only: You. You're the best. Go and have fun in your ludicrous road-legal supercar on your own, because everyone else is awful.
Find yourself a BAC Mono on Auto Trader.
Can't afford the £75k for a BAC Mono? Well, how about the Peel P50? One of the smallest cars ever made, there's barely space for you, let alone other people. It's basically a suit of armour to deflect the arrows that life - if not Cupid - fires at you. Which basically makes you a knight.
Sometimes you HAVE to take other people with you, but that doesn't mean you have to like them. Or talk to them. The dinky, electric Renault Twizy is a two seater, but the passenger goes at the back, where they can shut the hell up.
Find yourself a Renault Twizy on Auto Trader.
This fantastically amusing car from niche British car-maker Morgan sits two people next to each other in the traditional fashion. But with a very loud motorbike engine up front, and no bodywork or insulation to keep the noise down, you won't be able to hear anything they say. Great!
Find yourself a Morgan on Auto Trader.
McLaren's legendary supercar is famous for being very fast and very cool, but it also has an unusual interior layout where the driver sits in the middle at the front. Two passengers can fit in the back, but they're behind you, out of the way, and can talk to each other, rather than you. Good.
Find yourself a McLaren on Auto Trader.


There are a couple of issues that you might see when running the test example. The most serious issue is that even with a single point left the unit could still move onto a terrain tile that would cost two points. This is a serious problem because it ignores the movement point system that we have worked on until now. The second issue is less of an issue and more about the design of your war game; the example files still allow you to move your unit onto a terrain tile that already contains another unit. In your game, you may actually allow units to move on to the same terrain tile, and so you may not require any changes to the game.


text:
Switzerland and Singapore
Local and international news related to Switzerland and Singapore.
Swiss related events in Singapore
Job vacancies and internships at the Embassy
Articles and broadcasts about Switzerland in the Singapore media
Embassy of Switzerland in Singapore
The Swiss embassy represents Switzerland's interests in the country and provides consular services and visa support for people resident in: Singapore, Brunei Darussalam
The Swiss Business Hub promotes business ties between Switzerland and the ASEAN states.
Travel advice for Singapore
Dossier: Living and working in Singapore (PDF, Number of pages 27, 1.2 MB, French)
Celebrating the Swiss national holiday in the UK in 2012. © FDFA, Presence Switzerland
According to the Statistics on the Swiss Abroad compiled by the Federal Statistical Office, in 2020 around 776,300 Swiss citizens were registered with Swiss representations abroad. The Swiss community abroad has grown in recent years. If it were a canton it would be Switzerland's fourth largest in terms of population.
Contact the responsible Swiss representation for identity papers, civil status, registration and deregistration, matters of civil status, etc...
Information for the Swiss Abroad on the conditions to participate in popular votes at federal level and in elections to the National Council
Alongside various Swiss associations abroad, the OSA promotes relations among Swiss nationals and between the latter and their home country. It represents their interests in Switzerland, publishes the periodical «Swiss Review» and provides a broad range of services (e.g. youth exchange programmes, emergency assistance fund).
Organisation of the Swiss Abroad


Find your best-fitted mediterranean gifts from DHgate Canada site. Whether to comfort or decoration, we provide a range of styles to assist you in making appropriate choices of real kids gifts online. Cheap gift sticker sheets wholesale might be everywhere but those in ca.dhgate.com are strictly examined. Therefore you could take new grasslands wholesale gifts without hesitation. Search for perfect gift women sale of functional quality with free delivery to Canada from ca.dhgate.com.


text:
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY
(Exact name of registrant as specified in its charter)
(State or Other Jurisdiction
of Incorporation)
(Commission
File No.)
(IRS Employer
Identification No.)
Fifth Floor, Waterloo Exchange, Waterloo Road, Dublin 4, Ireland
(Address of principal executive offices, including zip code)
011-353-1-634-7800
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02. Results of Operations and Financial Condition.
On May 7, 2019, Jazz Pharmaceuticals plc (the "Company") issued a press release (the "Press Release") announcing financial results for the Company for the quarter ended March 31, 2019. A copy of the Press Release is furnished as Exhibit 99.1 to this current report.
The information in this Item 2.02 and in the Press Release furnished as Exhibit 99.1 to this current report shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the Press Release furnished as Exhibit 99.1 to this current report shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Item 9.01. Financial Statements and Exhibits.
Press Release dated May 7, 2019.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
/s/ Matthew P. Young
Matthew P. Young
Executive Vice President and Chief Financial Officer
JAZZ PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2019
Total Revenues Increased 14% to $508 Million
GAAP Diluted EPS of $1.47; Adjusted Diluted EPS of $3.67
Received FDA Approval of Sunosi for Excessive Daytime Sleepiness (EDS) Associated with Narcolepsy or Obstructive Sleep Apnea (OSA)
Announced Positive Top-line Results from Phase 3 Study of JZP-258 in Adult Narcolepsy Patients with Cataplexy and EDS
Launched Xyrem for Pediatric Narcolepsy
DUBLIN, May 7, 2019 -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the first quarter of 2019 and reaffirmed 2019 financial guidance.
"In the first quarter of 2019, we delivered strong top- and bottom-line growth and continued our efforts to bring innovative and life-changing medicines to patients, with FDA approval of Sunosi for EDS associated with narcolepsy or OSA, launch of Xyrem in pediatric narcolepsy and announcement of positive top-line results from our Phase 3 study of JZP-258," said Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals. "As the year progresses, we are continuing to invest in our business to support the successful launch of Sunosi in the U.S. and pre-launch activities in the EU, to generate data for our existing products and to fuel further advancement and diversification of our pipeline."
(In thousands, except per share amounts and percentages)
Total revenues
GAAP net income
Adjusted net income
GAAP EPS
Adjusted EPS
GAAP net income for the first quarter of 2019 was $85.2 million, or $1.47 per diluted share, compared to $46.0 million, or $0.75 per diluted share, for the first quarter of 2018.
Adjusted net income for the first quarter of 2019 was $213.2 million, or $3.67 per diluted share, compared to $182.4 million, or $2.98 per diluted share, for the first quarter of 2018. Reconciliations of applicable GAAP reported to non-GAAP adjusted information are included at the end of this press release.
Key Regulatory/R&D Updates
In March 2019, the company announced that the U.S. Food and Drug Administration (FDA) approved SunosiTM (solriamfetol) to improve wakefulness in adult patients with EDS associated with narcolepsy or
OSA. Sunosi is the first and only dual-acting dopamine and norepinephrine reuptake inhibitor approved by the FDA for this indication and was approved with strengths of 75 mg and 150 mg for patients with narcolepsy and 37.5 mg, 75 mg, and 150 mg for patients with OSA.
In March 2019, the company announced positive top-line results from the global, double-blind, placebo-controlled, randomized-withdrawal, multi-center Phase 3 study evaluating the efficacy and safety of JZP-258 for the treatment of cataplexy and EDS in adult patients with narcolepsy. JZP-258 is a novel oxybate product candidate with a 92% reduction in sodium content compared to Xyrem.
In March 2019, positive results from DEFIFrance, an observational, multi-center, post-marketing study in adult and pediatric patients treated with defibrotide at hematopoietic stem cell transplant centers in France, were presented at the European Society for Blood and Marrow Transplant (EBMT) meeting.
Select 2019 Milestones
2019 Milestones*
Xyrem® (sodium oxybate) oral solution
Launched in March for the treatment of cataplexy or EDS in pediatric narcolepsy
JZP-258
Announced positive top-line results in March from the Phase 3 narcolepsy study
Expect to submit top-line results from the Phase 3 narcolepsy study to a fall medical meeting
Pre-New Drug Application (NDA) meeting with FDA
Goal to submit NDA as early as year-end
Sunosi™ (solriamfetol)
FDA approval on March 20 for EDS in narcolepsy or OSA
Drug Enforcement Administration (DEA) scheduling decision by late second quarter
Initiate Sunosi launch following DEA scheduling decision
Announce new Phase 3 development program mid-year
Obtain EU approval for EDS in narcolepsy or OSA as early as year-end
Vyxeos® (daunorubicin and cytarabine) liposome for injection
Presentation by Children's Oncology Group at the American Society of Clinical Oncology (relapsed/refractory pediatric acute myeloid leukemia (AML) study data)
Potential interim combination data results from MD Anderson collaboration
Finalized protocol for Phase 1/2 study (low-dose Vyxeos in combination with venetoclax); patient enrollment is expected to begin in the second half of the year
Defitelio® (defibrotide sodium) / defibrotide
Presentation of positive results from DEFIFrance study at EBMT in March
Conduct interim analysis of the Phase 3 study for prevention of hepatic veno-occlusive disease (VOD)
Complete enrollment in prevention of acute graft-vs-host disease Phase 2 study
Initiate exploratory Phase 2 study in chimeric antigen receptor t-cell therapy associated neurotoxicity
Initiate Phase 2 study in transplant-associated thrombotic microangiopathy
Provide informational update on early-stage recombinant crisantaspase program later this year
CombiPlex®
Continue Investigational New Drug enabling activities for one solid tumor combination and progress exploratory activities for other hematology/oncology candidates
* Milestones denoted as a have been completed; all other milestones are planned or expected in 2019.
Other Developments
In March 2019, the company launched Xyrem to treat cataplexy and EDS in pediatric narcolepsy patients following receipt of FDA approval in October 2018 after completing implementation of the Risk Evaluation and Mitigation Strategy to include pediatric patients and their caregivers.
In April 2019, the company announced the finalization of the settlement agreement with the U.S. Department of Justice (DOJ) related to the company's support of charitable organizations that provide financial assistance to Medicare patients. In 2018, the company had announced an agreement in principle and recorded a total expense of $58.2 million related to this matter, including related interest. Under the settlement agreement, in April 2019, the company paid $57.0 million plus interest and entered into a five-year corporate integrity agreement with the Office of Inspector General of the Department of Health and Human Services.
(In thousands)
Erwinaze® / Erwinase® (asparaginase Erwinia chrysanthemi)
Product sales, net
Royalties and contract revenues
Total revenues increased 14% in the first quarter of 2019 compared to the same period in 2018.
Xyrem net product sales increased 16% in the first quarter of 2019 compared to the same period in 2018.
Erwinaze/Erwinase net product sales increased 20% in the first quarter of 2019 due to an increase in product availability compared to the same period in 2018. The company continues to expect supply disruptions throughout 2019 which will cause inter-quarter variability in Erwinaze net sales.
Defitelio/defibrotide net product sales increased 18% in the first quarter of 2019 compared to the same period in 2018 due to increased use by transplant centers that treat adult and pediatric patients. VOD is an ultra-rare disease and, as a result, the company continues to expect inter-quarter variability in Defitelio net sales.
Vyxeos net product sales increased 10% in the first quarter of 2019 compared to the same period in 2018 primarily due to the rolling launch in the EU initiated in September 2018. The company continues its education and outreach initiatives and its efforts to generate data to support Vyxeos' potential use across broader patient populations in AML and other hematological malignancies.
(In thousands, except percentages)
GAAP:
Cost of product sales
Gross margin
Selling, general and administrative
% of total revenues
Acquired in-process research and development
Income tax provision
Non-GAAP adjusted:
Operating expenses changed over the prior year period primarily due to the following:
Selling, general and administrative (SG&A) expenses on a GAAP basis decreased in the first quarter of 2019 compared to the same period in 2018 primarily due to a $57.0 million loss contingency recorded in 2018 related to the DOJ matter described above. SG&A expenses on a GAAP basis, excluding the impact of the loss contingency, and on a non-GAAP adjusted basis increased in the first quarter of 2019 compared to the same period in 2018 primarily due to higher expenses related to the planned launch of Sunosi in the U.S. and an increase in headcount and compensation-related expenses to support expansion of the business.
Research and development (R&D) expenses on a GAAP basis decreased in the first quarter of 2019 compared to the same period in 2018 primarily due to milestone payments of $11.0 million related to FDA acceptance for filing of the company's solriamfetol NDA recorded in 2018. R&D expenses on a GAAP basis, excluding the impact of milestone payments, and on a non-GAAP adjusted basis increased in the first quarter of 2019 compared to the same period in 2018 primarily due to expenses related to the company's pre-clinical and clinical development programs, including partner programs, regulatory activities and related headcount increases to support these efforts.
Cash Flow and Balance Sheet
As of March 31, 2019, cash, cash equivalents and investments were $832.5 million and the outstanding principal balance of the company's long-term debt was $1.8 billion. During the first quarter of 2019, the company generated $202.3 million of cash from operations, made an upfront payment of $56.0 million to Codiak BioSciences, Inc. under a collaboration agreement and used $111.2 million to repurchase shares.
In the first quarter of 2019, the company repurchased approximately 858,000 ordinary shares under the company's share repurchase program at an average cost of $129.66 per ordinary share. As of March 31, 2019, the remaining amount authorized for share repurchases was $267.9 million.
2019 Financial Guidance
Jazz Pharmaceuticals is reaffirming its full year 2019 financial guidance as follows (in millions, except per share amounts and percentages):
Revenues1
Total net product sales1
-Xyrem net sales
-Erwinaze/Erwinase net sales
-Defitelio/defibrotide net sales
-Vyxeos net sales
GAAP gross margin %
Non-GAAP adjusted gross margin %2,6
GAAP SG&A expenses
Non-GAAP adjusted SG&A expenses3,6
GAAP R&D expenses
GAAP Acquired in-process research and development expenses
Non-GAAP adjusted R&D expenses4,6
GAAP effective tax rate
Non-GAAP adjusted effective tax rate5,6
GAAP net income per diluted share
Non-GAAP adjusted net income per diluted share6
Includes minimal net sales contribution from Sunosi in the U.S., assuming launch in mid-2019.
Excludes $6-$8 million of share-based compensation expense from estimated GAAP gross margin.
Excludes $82-$90 million of share-based compensation expense from estimated GAAP SG&A expenses.
Excludes $0-$34 million of milestone payments and $22-$27 million of share-based compensation expense from estimated GAAP R&D expenses.
Excludes the income tax effect of adjustments between GAAP reported and non-GAAP adjusted net income.
See "Non-GAAP Financial Measures" below. Reconciliations of non-GAAP adjusted guidance measures are included above and in the table titled "Reconciliation of GAAP to Non-GAAP Adjusted 2019 Net Income Guidance" at the end of this press release.
Jazz Pharmaceuticals will host an investor conference call and live audio webcast today at 4:30 p.m. EDT (9:30 p.m. IST) to provide a business and financial update and discuss its 2019 first quarter results. The live webcast may be accessed from the Investors section of the company's website at www.jazzpharmaceuticals.com. Please connect to the website prior to the start of the conference call to ensure adequate time for any software downloads that may be necessary. Investors may participate in
the conference call by dialing +1 855 353 7924 in the U.S., or +1 503 343 6056 outside the U.S., and entering passcode 6667859.
A replay of the conference call will be available through May 14, 2019 by dialing +1 855 859 2056 in the U.S., or +1 404 537 3406 outside the U.S., and entering passcode 6667859. An archived version of the webcast will be available for at least one week in the Investors section of the company's website at www.jazzpharmaceuticals.com.
Non-GAAP Financial Measures
To supplement Jazz Pharmaceuticals' financial results and guidance presented in accordance with U.S. generally accepted accounting principles (GAAP), the company uses certain non-GAAP (also referred to as adjusted or non-GAAP adjusted) financial measures in this press release and the accompanying tables. In particular, the company presents non-GAAP adjusted net income (and the related per share measure) and its line item components, as well as certain non-GAAP adjusted financial measures derived therefrom, including non-GAAP adjusted gross margin percentage and non-GAAP adjusted effective tax rate. Non-GAAP adjusted net income (and the related per share measure) and its line item components exclude from reported GAAP net income (and the related per share measure) and its line item components certain items, as detailed in the reconciliation tables that follow, and in the case of non-GAAP adjusted net income (and the related per share measure), adjust for the income tax effect of non-GAAP adjustments. In this regard, the components of non-GAAP adjusted net income, including non-GAAP cost of product sales, non-GAAP SG&A expenses and non-GAAP R&D expenses, are income statement line items prepared on the same basis as, and therefore components of, the overall non-GAAP adjusted net income measure.
The company believes that each of these non-GAAP financial measures provides useful supplementary information to, and facilitates additional analysis by, investors and analysts. In particular, the company believes that each of these non-GAAP financial measures, when considered together with the company's financial information prepared in accordance with GAAP, can enhance investors' and analysts' ability to meaningfully compare the company's results from period to period and to its forward-looking guidance, and to identify operating trends in the company's business. In addition, these non-GAAP financial measures are regularly used by investors and analysts to model and track the company's financial performance. Jazz Pharmaceuticals' management also regularly uses these non-GAAP financial measures internally to understand, manage and evaluate the company's business and to make operating decisions, and compensation of executives is based in part on certain of these non-GAAP financial measures. Because these non-GAAP financial measures are important internal measurements for Jazz Pharmaceuticals' management, the company also believes that these non-GAAP financial measures are useful to investors and analysts since these measures allow for greater transparency with respect to key financial metrics the company uses in assessing its own operating performance and making operating decisions.
These non-GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable GAAP measures; should be read in conjunction with the company's consolidated financial
statements prepared in accordance with GAAP; have no standardized meaning prescribed by GAAP; and are not prepared under any comprehensive set of accounting rules or principles. In addition, from time to time in the future there may be other items that the company may exclude for purposes of its non-GAAP financial measures; and the company has ceased, and may in the future cease, to exclude items that it has historically excluded for purposes of its non-GAAP financial measures. Likewise, the company may determine to modify the nature of its adjustments to arrive at its non-GAAP financial measures. Because of the non-standardized definitions of non-GAAP financial measures, the non-GAAP financial measures as used by Jazz Pharmaceuticals in this press release and the accompanying tables have limits in their usefulness to investors and may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by other companies.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995
This press release contains forward-looking statements, including, but not limited to, statements related to Jazz Pharmaceuticals' future financial and operating results, including its 2019 financial guidance, the company's planned or expected 2019 milestones and the timing thereof, the company's continuing investments to support a successful launch of Sunosi in the U.S. and EU pre-launch activities, to generate data for its existing products and to fuel further advancement and diversification of its pipeline, the company's expectations of further Erwinaze supply disruptions and inter-quarter variability in Erwinaze and Defitelio net sales, the company's plans to generate data to support existing products, including Vyxeos' potential use across broader patient populations in AML and other hematological malignancies, and other statements that are not historical facts. These forward-looking statements are based on the company's current plans, objectives, estimates, expectations and intentions and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with: maintaining or increasing sales of and revenue from Xyrem; effectively commercializing the company's other products and product candidates, including the risk of a potential delay in the commercial launch of Sunosi in the U.S. due to the DEA scheduling review or otherwise; the time-consuming and uncertain regulatory approval process, including the risk that the company's regulatory submissions, including the Sunosi marketing authorization application in the EU, may not be approved by applicable regulatory authorities in a timely manner or at all; costly and time-consuming pharmaceutical product development and the uncertainty of clinical success, including risks related to failure or delays in initiating or completing clinical trials; protecting and enhancing the company's intellectual property rights; delays or problems in the supply or manufacture of the company's products and product candidates; complying with applicable U.S. and non-U.S. regulatory requirements; government investigations and other actions; obtaining and maintaining adequate coverage and reimbursement for the company's products; identifying and acquiring, in-licensing or developing additional products or product candidates, financing these transactions and successfully integrating acquired businesses; the ability to achieve expected future financial performance and results and the uncertainty of future tax and other provisions and estimates; and other risks and uncertainties affecting the company, including those described from time to time under the caption "Risk Factors" and elsewhere in Jazz Pharmaceuticals plc's Securities and Exchange Commission filings and reports (Commission File No. 001-33500), including the company's Annual Report on Form 10-K for the year ended December 31, 2018 and future filings and reports by the company, including the company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2019. Other risks and uncertainties of which the company is not currently aware may also affect the company's forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(In thousands, except per share amounts)
Revenues:
Operating expenses:
Cost of product sales (excluding amortization of intangible assets)
Intangible asset amortization
Total operating expenses
Interest expense, net
(17,922
Foreign exchange loss
(611
(1,728
Income before income tax provision and equity in loss of investees
Equity in loss of investees
Net income per ordinary share:
Weighted-average ordinary shares used in per share calculations - basic
Weighted-average ordinary shares used in per share calculations - diluted
CONDENSED CONSOLIDATED BALANCE SHEETS
Current assets:
Accounts receivable, net of allowances
Other current assets
Total current assets
Property, plant and equipment, net
Operating lease assets
Intangible assets, net
Deferred tax assets, net
Deferred financing costs
Other non-current assets
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Accrued liabilities
Current portion of long-term debt
Income taxes payable
Deferred revenue
Total current liabilities
Deferred revenue, non-current
Long-term debt, less current portion
Operating lease liabilities, less current portion
Deferred tax liabilities, net
Other non-current liabilities
Total shareholders' equity
Total liabilities and shareholders' equity
SUMMARY OF CASH FLOWS
Net cash provided by operating activities
Net cash provided by (used in) investing activities
Net cash used in financing activities
(130,349
Effect of exchange rates on cash and cash equivalents
Net increase in cash and cash equivalents
RECONCILIATIONS OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION
GAAP reported net income
Share-based compensation expense
Loss contingency
Upfront and milestone payments
Non-cash interest expense
Income tax effect of above adjustments
Non-GAAP adjusted net income
GAAP reported net income per diluted share
Non-GAAP adjusted net income per diluted share
Weighted-average ordinary shares used in diluted per share calculations
CERTAIN LINE ITEMS AND OTHER INFORMATION
GAAP Reported
Non-GAAP Adjusted
Effective tax rate (g)
Net income per diluted share
Explanation of Adjustments and Certain Line Items (in thousands):
Share-based compensation expense of $1,659 and $1,694 for the three months ended March 31, 2019 and 2018, respectively.
Share-based compensation expense of $20,370 and $18,234 and loss contingency of $0 and $57,000 for the three months ended March 31, 2019 and 2018, respectively.
Share-based compensation expense of $5,523 and $4,375 and upfront and milestone payments of $0 and $11,000 for the three months ended March 31, 2019 and 2018, respectively.
Non-cash interest expense associated with debt discount and debt issuance costs for the respective three-month period.
Sum of adjustments (a) through (d) plus the adjustments for intangible asset amortization and acquired in-process research and development, as applicable, for the respective three-month period.
Income tax adjustments related to the income tax effect of adjustments between GAAP reported and non-GAAP adjusted net income for the respective three-month period.
Income tax provision divided by income before income tax provision and equity in loss of investees for the respective three-month period.
Net of adjustments (e) and (f) for the respective three-month period.
RECONCILIATION OF GAAP TO NON-GAAP ADJUSTED 2019 NET INCOME GUIDANCE
Intangible asset amortization*
Income tax effect of adjustments
(75) - (95)
Weighted-average ordinary shares used in per share calculations
* Updated May 7, 2019.
Kathee Littrell
Ireland, +353 1 634 7887
U.S., +1 650 496 2717


Reconstruction of tissue defects with skin grafts is one of the most used processes in soft tissue defects. While any part of the body can be used as a donor site of split-thickness skin grafts, the posterolateral thigh is the most used one. Pain in the graft donor site may be the primary concern of patients in the postoperative period. Various kinds of donor site dressings and procedures have been described for this purpose. The main goal of this practice is the fast recovery of the donor site. Nevertheless, avoiding infection, decreasing the pain in the donor site, and minimizing the cost should be considered. To minimize pain in the graft donor site, ice pack application, used for its local anesthetic effect, was utilized for patients postoperatively in our clinic. Thirty-six patients were included in this study between June 2001 and May 2002. Patients were divided into two groups, with 18 patients in-group I, to whom ice was applied, and 18 patients in group II, which was specified as the control group. The patients were evaluated according to the pain in the graft donor site. The visual analog scale (VAS) was used to evaluate the pain of the patients. The data were statistically evaluated with the Mann–Whitney U test procedure. In addition to this, infections, recovery periods, and cost benefit effects were also determined. The mean pain scores in the graft donor site were found to be quite low in patients in the group with ice application (p < 0.05). No significant difference was determined between the two groups when their pain scales were compared on the fourth and the fifth days (p > 0.05). Ice can be safely used in patients for whom donor site pain is the primary concern, with advantages such as ease of application, low cost (almost free), and a significant decrease in pain in the donor site.


Before yesterday, I hadn't planned to write about the Boston Marathon, despite its importance in our house. Some years, my husband arranges to be off the day of the marathon so we can watch coverage of it, but yesterday, he had to go in to work.
Instead of writing about Boston, I had been planning to write tomorrow about an inspiring couple who just completed the same 100-mile race as my husband two weekends ago. I still might write about them tomorrow, or I might wait until next week. I'm not sure yet, because I want their story to count, and I don't want it to get lost in the tragic events of this week.
You see, my family of runners came under attack yesterday, and I'm hurt and angry and confused and grief-stricken. The sick-stomach feeling hasn't left me since I heard the news yesterday afternoon. And I know I have to write about it here before I can move on to happier topics.
I'm not going to take time to photograph anything for today's post. There's nothing I could include here that could add anything meaningful to what I need to say about yesterday – not the medals or jackets my husband has earned in Boston, not the framed Boston Marathon posters that grace our walls, not even the books on our shelves that tell the many stories of this great event.
If you're not a runner, you may not quite understand the nature of runners that makes us all feel part of a community, part of a large, slightly crazy family. If you are a runner, you know what I mean. And Boston? Well, Boston is the most prestigious family party we have in the United States every year (dare I name it the best in the world?). We all want to be invited, and many of us work for years to qualify for the opportunity to go. Some of us know we will never go as anything other than spectators. When we meet other runners, and the conversation turns to Boston, we know what comes next: "Have you run it?" The simple one-word answer to that question is telling for everyone who has ever run a marathon and knows what sets Boston apart. You have to run for real to get to Boston.
Before two bombs changed everything yesterday afternoon, I watched Kara Goucher come across the finish line. Her first words after she finished were about her teammate and training partner Shalane Flanagan. "How'd Shalane do? How'd Shalane do?" That answer was more important to Goucher than anything else in that moment, more important than how she felt and more important than her impressive 6th place finish. She wanted to know how her "sister" had fared in the event. Goucher knows: we runners are stronger together, more resilient when we cheer each other's accomplishments and not just our own.
I spent much of the later part of the afternoon praying, watching my Twitter feed for news, and answering phone calls, texts and Facebook inquiries from friends who wanted to know if we were in Boston (we had not traveled to Boston); whether we knew anyone running yesterday (several friends of friends and also some of my husband's colleagues); and whether we were okay ourselves (shaken, angry, confused). Friends of my parents called them to make sure Chris and I were okay, and I called my mother-in-law so she would hear the news from me before any friends had a chance to call her with their own questions of concern.
I didn't watch much coverage of the aftermath (see There but for the grace of God), but I did spend time looking for people's names on the Boston Marathon runner tracker page, trying to assume that those who had an official finish time were most likely safe. Some were the friends of friends I mentioned, but others were complete strangers, like the two sweet women who were running Boston yesterday to raise money for friends' medical expenses. I didn't even know their story until yesterday, and yet I found myself searching for word that they were okay, safe, whole.
I did watch the nations' flags flutter and a few fall in the aftermath. This was an attack on U.S. soil, but it was also an attack on all of us. As Donne says, "No man is an island." Flags fly at half staff in my own city today, a show of solidarity, an announcement that we are with Boston and with those who face unimaginable injury and unimaginable loss of life. And we will lend our best to help make the Boston marathon even stronger next year.
There's an 8-year-old boy among the dead. And I think I won't be able to push him out of my thoughts as I head off for the last coaching session with my own team of 8-year-old and older girls. Because I know that we are a running family, and his death and the terror of yesterday diminished us all in some way.
But I also know that runners are resilient. We wouldn't be able to accomplish great distances without that toughness. And we will band together. And we will be stronger than terror wants us to be. And we will be loving in a way that terror can never understand. And we will care about those whom terror has killed or injured. And we will triumph. And we will raise the flags along Boylston Street again. And we will run.
This entry was posted in runners' devotion and tagged Boston, Boston marathon, kara goucher, marathons, resilience, runners, running, shalane flanagan, terror by hopesquires. Bookmark the permalink.
I spent yesterday trying to regroup and found myself wandering the galleries of an art museum. I heal through running, gardening, art and music, and time with family and friends. How do you find solace and healing, and how do you recapture joy after (or during) tragedies like this?
One more thing- when SG and I talked of this tonight, she looked at me with horror and confusion when she realized it happened during a running event. I am sure she connected it to her gotr race on Saturday. You are wise to think of your girls in this context.
Tricia — as always, thanks for your kind words. I'm sad that I have to think this way on behalf of the precious little girls I have the honor of coaching. I hope SG will feel safe as she runs in the future. So young to carry such a burden.
So moving and passionate. I learned a lot. This is the passion I felt after Newtown. Thanks for sharing your gift.
This is such a thoughtful and moving post, Hope. Thank you for sharing your reactions.


text:
Una contradicción performativa () surge cuando el contenido proposicional de una declaración contradice los presupuestos de afirmarla. Un ejemplo de contradicción performativa es la declaración "estoy muerto", porque el mismo acto de proponer presupone que el actor está vivo.

Uso en filosofía
A menudo se argumenta que el solipsismo constituye una contradicción performativa al ser declarado. Si no se declara, se considera habitualmente como un ejemplo de la aplicación normativa del qui tacet consentire videtur (el que calla consiente).
Jürgen Habermas y filósofos afines señalan que las afirmaciones dichas durante las argumentaciones justificativas traen presuposiciones adicionales y, por tanto, que algunas son contradicciones performativas en este contexto. Habermas sostiene que el relativismo epistemológico posmoderno adolece una contradicción performativa.

Jaakko Hintikka desarrolló más rigurosamente la noción de contradicción performativa al analizar el famoso argumento del cogito ergo sum de Descartes, concluyendo que el cogito ergo sum se basa en la actuación más que en la inferencia lógica.

Véase también

 Contradicción
 Ética del discurso
 Paradoja del mentiroso
 Paradoja
 Lógica

Bibliografía

Gramática
Filosofía del lenguaje
Paradojas


James Murabito of Harrison graduates with a Bachelor of Science in Mechanical Engineering degree from Lehigh University in Spring 2018.
During Commencement ceremonies on May 21, 2018, Lehigh University conferred 1,103 Bachelor's degrees, 402 Master's degrees and 59 Doctoral degrees. Of the more than 1,500 graduates, degree recipients came from 42 states and 53 countries, majoring in 91 different disciplines.


text:
Contact PALS: online form
At the Royal Free London NHS Foundation Trust, we are fully committed to providing a high quality patient experience.
To help us achieve that aim, the patient advice and liaison service (PALS) offers support, information and assistance to patients, relatives and visitors about medical services and hospital care. Find out how PALS can help you.
Please be aware that the PALS team will need to access the hospital's appointment system, your medical records and liaise with other departments in order to be able to help you with your enquiry.
You can get in touch with the PALS teams at any of our hospitals via our online form.
Contact us by telephone
If you wish to speak to someone on the telephone, please use the numbers below:
Barnet Hospital PALS: 020 8216 4924
Chase Farm Hospital PALS: 020 8375 1328
Royal Free Hospital PALS: 020 7472 6446 or 020 7472 6447
Please note: PALS do not deal with requests for volunteer opportunities, work experience, references or invoices and will not be able to assist in these matters.
The PALS team at Barnet Hospital
The patient advice and liaison service for Barnet Hospital is based on the ground floor of Barnet Hospital, near the main entrance.
It is open Monday to Friday, from 10am-4pm. You can contact PALS using the details below:
Email: bcfpals@nhs.net
Write to us: patient advice and liaison service (PALS), Barnet Hospital, Wellhouse Lane, Barnet EN5 3DJ
Visit us: We are open for visitors Monday to Friday, 10am-4pm. You will find us on the ground floor of Barnet Hospital, near the main entrance.
The PALS team at Chase Farm Hospital
The Patient Advice and Liaison Service is provided by the Patient Experience Team and is available from Monday to Friday between 10am and 4pm. The Patient Experience Team can be contacted using the following methods:
Email: rf-tr.cfhpals@nhs.net
Should you wish to speak to a member of the Team whilst at the hospital please ask a member of staff to call the Patient Experience Team on ext: 51328. A member of the team will arrange to meet with you.
The PALS team at the Royal Free Hospital
The patient advice and liaison service for the Royal Free Hospital in the hospital's main reception.
The service is open from 10am to 4pm, Monday to Friday, except Wednesday, when the service is open from 10.30am to 4pm.
7 August, 11 August, 14 August – closed
You can contact the team using the following details:
Tel: 020 7472 6446/6447; (020 7472 6445 - 24 hour answer phone)
SMS: 447860023323 (Deaf, hard of hearing and hearing impaired patients only)
Email: rf.pals@nhs.net
Please note: Change in hours at the Royal Free Hospital from 7 August to 16 August
From 7 August – 17 August phones will only be manned between the hours below:
10–12pm and 2-4:30pm
Download our leaflet to find out more about our service.
Support to make a complaint about our medical services
If you are staying with us, or visiting someone who is, the best person to talk to is the nurse in charge or the matron of the ward. If you are visiting a hospital clinic, you can ask reception to put you in touch with the member of staff you need to talk to. Alternatively you can use our online feedback forms (see below).
Complain about Barnet Hospital
Complain about Chase Farm Hospital
Complain about the Royal Free Hospital
If you are dissatisfied with the service you have received at any of our hospitals, our complaints team will also be happy to help you. Find out how to make a complaint.
If you would like independent advice and support, the advocacy services below are available:
VoiceAbility works across England with people who are vulnerable or marginalised to raise their voices and have their rights respected.
NHS Complaints Advocacy United House, 39-41 North Road, London N7 9DP www.nhscomplaintsadvocacy.org and www.voiceability.org
POhWER provides advocacy service for patients resident in Hertford shire, Bedfordshire and Luton.
NHS Complaints Advocate Head Office Hertlands House Primett Road, Stevenage, SG1 3EE Tel: 0300 456 2370 Fax: 0300 456 2365 Minicom: 0300 456 2364 Website: www.pohwer.net Email: pohwer@pohwer.net
Change, cancel or enquire about your hospital appointment


text:
Hexamethyldisilazaan
 Hexamethyldisiloxaan


Tudor, Tasha. New York & Cleveland: The World Publishing Company, 1970. 1st edition. 7 1/2" x 6 5/8"
302 +  pp. The book is Very Good with darkened edges and light wear to the tail piece. Dust jacket is complete with small edge chips and is discolored from age along the edges. The book is special by the typical inscription from Campbell on the half-title: With best wishes Mary Mason Campbell. There is also a personalized gift inscription 1972 on page . Birthdays are recorded in Sept., Oct., Nov., and Dec.
Inscribed by Campbell on half-title.


The Insurance Verification Coordinator-Managed Care maintains and coordinates all aspects of insurance verification and demographic payer information. Assists with new authorizations and ongoing re-authorizations as coordinated with the Managed Care Coordinator.
High School Graduate. Associates Degree preferred. . Home Health experience required, prior experience in managed care, insurance knowledge a plus.
Ability to pay close attention to detail and work independently. Ability to multi-task and prioritize. Good communications and interpersonal skills. Must be a team player. Proficiency with common office software programs.


The flame lit by 'Krantijyoti' Savitribai Phule has been kept burning by a women's volunteer organization in Pune, the very city in which India's social revolution was launched. In an ordinary flat on Agrasen High School Road in the Yerwada area, the organization appropriately named Krantijyoti is taking forward the legacy of Savitribai Phule.
What's so special about this organization is that women who run it all come from the Dalitbahujan communities and are trained and organized in carrying on the fight to live with dignity. The women believe that whether it is in a village or a city, women are highly discriminated against. Inspired by the freedom women had in the movements led by Dalibahujan icons Jotiba Phule and Dr Babasaheb Ambedkar these women are moving ahead with a sense of keeping their legacy alive. They say that in the Indian Constitution everyone has been given equal rights irrespective of caste, creed, class and gender. However, in social life the advocates of the hierarchy-based order continue to deprive women of their rights, and because of this women are forced to be always dependent on others and be forever demoralized.
To help women come out of this demoralized state, a young woman, Archana, who was born and brought up in Yashoda Nagar in Amravati district of northeast Maharashtra, got together with a few local women and laid the foundation of an organization called Krantijyoti (The Light of Revolution). Archana is the coordinator of the organization, whose priority is to make women self-confident and fearless. It is because if women gain self-confidence, they will be able to identify the problems plaguing themselves, their families and the community and will also initiate efforts in finding solutions.
Women come to the Krantijyoti office to get training. Archana says that Krantijyoti's basic objective is to promote the ideas of Jotiba and Savitribai Phule and thus inculcate in women the sense and desire of being educated and fulfilling their social responsibilities. She says that after her marriage in 2010, she borrowed some money and rented this house to fulfil her objective. Today, she has registered the organization as a trust and is working towards empowering women and making them literate and fearless, besides turning them – and herself – into able leaders.
Krantijyoti organized CLTP, a community-level leadership development programme. Because of this leadership-development programme, many Bahujan women have been empowered to solve their own problems. Besides, they have also begun to turn their attention to the problems faced by their settlements or communities. Many of these women, who had barely stepped outside their house and lacked the confidence to even say their names, are now discussing their problems at various platforms quite candidly and also taking steps to solve them.
Krantijyoti is also determined to help women find employment. Women associated with this organization are being trained in entrepreneurial development and are becoming self-dependent. Krantijyoti has eight full-time workers and there are more than 40 volunteers serving with the organization. Not only that, there is a strong network of more than 600 women. Thus we can say that Krantijyoti is truly giving wings to Savitribai Phule's dream of uplifting the status of women.
There are diverse departments to empower women. Krantijyoti Study and Training Centre (KSTC) and Ramai Business Training Centre (RBTC) are two prominent programmes. There is also a Krantijyoti Vichar Manch (Krantijyoti Ideas Forum) through which dialogue is initiated with women outside the network. The manch regularly runs awareness programmes through discussion sessions, competitions, camps and workshops. Not only that, the organization promotes education through a Krantijyoti Scholarship Scheme for girl students from Class VII to IX. It does so by holding a scholarship exam, after which nine girls are given scholarships of Rs 2,000 each.
Archana had also started a weekly magazine for the social, intellectual, educational, financial, health and personality development of Krantijyoti women but it had to be closed down after 16 issues due to financial difficulties. Even today, despite plenty of hardships, Krantijyoti is spreading the light of revolution among women and taking forward the legacy of Savitribai Phule's social work.


Lets get right down to it: harpist Edmar Castaneda's Double Portion is an early contender for record of the year.
If your only experiences with the harp are undulating and shimmering glissandos in movie soundtracks or perhaps hearing a harpist at a wedding playing transcriptions of Bach, then Castaneda's playing will more than likely come as a revelation. Double Portion opens up a whole new world of the harp's possibilities.
Dorothy Ashby's music is hip, and she did some great things in both more straight ahead and soul jazz veins. Alice Coltrane was certainly an innovative force on the instrument and produced several classic free jazz performances. On Double Portion Castaneda is in a completely different bag than Ashby and Coltrane, and brings a level of creativity and virtuosity that is on par, if not exceeding his harp predecessors.
Whereas Coltrane often favored idiomatic glissandos to create waves of sound, Castaneda takes an approach that almost sounds guitar-like. In fact his harp, especially the Colombian harp, often sounds like a large guitar, which is very apparent on the five solo cuts.
To see where Castaneda is coming from and to get his approach directly from the source, watch the EPK video below, where he describes how his music is a mixture between Colombia and New York and how he uses the harp in a new way: namely by playing the bass and the melody at the same time.
Castaneda wrote nine of the album's ten compositions – the only cover being Astor Piazolla's "Libertango," which features Hamilton de Holanda on mandolina.
Joining Castaneda on two tracks is pianist Gonzalo Rubalcaba (who has also recently released an excellent solo album). Rubalcaba and Castaneda double the melody of the title track, which opens the album, creating timbres rarely heard. Castaneda supports Rubalcaba's solo with strong bass lines, the resonance and sonic heft of which left me stunned upon first hearing them. The interplay between both musicians is excellent, and the line between soloist and accompanist is often blurred, if not erased altogether. The other Castaneda/Rubalcaba duet, "Quitapesares," is also excellent, and contains several different rhythmic feels and grooves. The final flourish is quite impressive, with both men repeating developing short, punctuated statements that grow in energy, intensity and volume.
MacArthur Genius award winning alto saxophonist Miguel Zenon is also a guest, and his collaboration with Castaneda on "A la Tierra" is one of the album's high points. Here Castaneda plays bass lines while his other hand intertwines with Zenon, who is his usual impassioned and inspired self. After Zenon finishes his solo Castaneda plays an angular bass line and predominantly single note melody lines – which is a nice contrast to the thicker textures earlier in the tune. Zenon enters, accompanying Castaneda, who ratchets up the tension with tight and percussive notes and chords that increase in intensity and agitation before resolving, concluding the piece with a brief, but calm and ethereal coda.
Double Portion is a blend of musical styles, of cultures, and is a thoroughly original, ingenious and moving album that will leave you simultaneously bopping your head in time and shaking it in amazement. If any of the above piques your interest in checking out Castaneda's Double Portion, then do yourself a favor and buy the album, and listen to it again, and again, and again.
Sounds great. Download only? CD used to be at least a minimum. I vote for high resolution downloads for this album!


text:
Penn State ag economist says rising food prices not the farmers' fault
by Pennsylvania State University
Wholesale food prices rose last month by the most in 36 years, and experts can't say how high they'll ultimately go. As the effects appear everywhere from the supermarket to fast food restaurants, an economist in Penn State's College of Agricultural Sciences said farmers probably won't be reaping much of the increase.
James Dunn, professor of agricultural economics, said prices for corn, wheat, soybeans and just about all large-production crops are higher than they were one year ago. He points to a long-term increase in global demand as the most salient of several factors.
"We had a big spike in commodity prices in 2007-2008, when there was a good worldwide economy and the prices of everything went high that year, too," he said. "Then the global recession hit. As we come out of it, we're seeing increasing demand resume. Then last season's bad weather in northern Europe, Poland and Russia really hit the feed-grain markets."
The United States typically exports grain to cover worldwide shortfalls, but U.S. production also faltered last year. Demand for soybeans outstripped supply despite a record crop, and there was record demand for wheat. It all results, Dunn said, in a perfect storm for high commodity prices.
"Last year was a particular challenge, and we're going into this growing season with a very small crop inventory," he said. "Ethanol production now consumes nearly 40 percent of the nation's corn crop, up from about 10 percent a decade ago, and there's growing demand for meat and dairy products in places like India and China.
"The combination of more people, low agricultural production and weather snafus means we'll have pretty high commodity prices for the next year or so."
Dunn cautioned that the current high food prices originate at the farm level, but few people buy food at the farm level. Most of the modern American food dollar goes to processing, transportation and marketing and not to the producers. So, rising farm prices won't hit all foods equally.
"The fact that corn prices are doubled doesn't mean that foods made from corn will double," he said. "In fact, the basic commodities are a relatively small portion of retail food prices. Labor, packaging, transportation and processing represent the majority of your food prices, and those don't change as rapidly as farm commodities.
"The actual food-cost increase will vary, first according to what percentage of the retail price the farm value represents, and second, how much the commodity price has gone up, because all commodities haven't risen equally," he said. "So we're going to see particular items in our market basket cost more. Some of them, like milk, have a fairly large component in the retail price, and so if milk prices are higher, the consumers will notice that."
Most products have a fairly small agricultural component, but Dunn says some manufacturers won't let these facts hinder their pricing strategies.
"Sometimes the processor will use the excuse of higher farm prices to recoup some profit that slipped away because of other input costs," he said. "We've seen cereal companies cite high corn prices when raising their prices much higher than the value of the corn in the flakes.
"Sometimes you can increase the palatability of a price increase with an argument that sounds better than it actually is."
Internationally, the specter of high food prices is much more threatening. Dunn explained that for countries with lower standards of living than the United States, high commodity prices could bring serious hardship. And it may not be limited to nations that traditionally struggle with poverty.
"For example, in Ukraine, which seems like a relatively prosperous country, about 50 percent of their income is spent on food," he said. "So, when food prices go up quite a bit, their real income goes down sharply. Americans only spend 10 percent of their income on food, so the doubling of commodity prices is less important.
"And if you're spending half your income on food, you're not buying a lot of processed product. You're buying unprocessed ingredients, and they're more like the commodities -- they'll go up and down more than pizzas and things that have a lot of marketing in them already. But for onions and potatoes, the farm value is a big part of the retail price."
Study predicts crop-production costs will jump dramatically in 2009
Provided by Pennsylvania State University
Citation: Penn State ag economist says rising food prices not the farmers' fault (2011, April 5) retrieved 19 January 2022 from https://phys.org/news/2011-04-penn-state-ag-economist-food.html
Question About Electric Aircraft Propulsion
A few questions about Potential Energy
Test a cheap Surge Protector Power Strip (US 110V)?
What do they mean when they say something is so many light years away
Is the concept of "wave function collapse" obsolete?
Graduate Quantum as an Undergrad
More from Physics Forums | Science Articles, Homework Help, Discussion
New study says high grain prices are likely here to stay
Report: Ethanol raises cost of nutrition programs
Three billion Asians face food crisis threat: research
Researcher looks at the future of agriculture
Biofuel mandates would make corn shortfall costly, experts say
Rainy days harm the economy: study
Study: Economic progress is aided by longer supply chains and deeper networks
How you speak up at work can affect whether you're picked for a team
Extroverted? You may have better financial outcomes
Study: AI technology no silver bullet for hiring the best employees
Researchers caution global economic growth could slide into stagnation


Put a smile on the kids faces when Rudolf shows up as a tasty treat!
Follow these simple step by steps to see how.
Cover your cup cake with either butter cream or jam (that doesn't have fruit in it).
This helps to smooth out bumps and keep your cake moist.
Using a round cutter the size of your cup cake, cut a piece from thinly rolled fondant and lay it on your cup cake to create the face.
I've used white like snow here.
Using a smaller cutter (about a third of the size of the cup cake), cut out circles of chocolate fondant. these will be the raindeer faces.
Using a smaller cutter again (about half the size of the one used to create the raindeer faces) cut a circle for each cup cake. These will be for the ears.
Cut each of the smaller circles in half. Each half will make one ear.
Using the end of a paint brush or skewer, fold the circle along in half along the straight edge then pinch it together.
Using a little water as glue on both the faces and ears, position each ear under the face at the bottom of the cup cake. Remember, you need to leave room for the antlers!
Using a sharp knife or pizza cutter, make some thin strips out of the left over chocolate fondant.
Using the small circle cutter, cut some semi circles out of the outer edges of two matching strips.
Using water as glue, attach these to the top of your raindeers head. Bend them into shape as you attach them.
Using the smaller circle cutter (make sure you clean it before using it with a different colour) cut a round red nose for each cup cake.
Using a little water, attach it to the bottom of your raindeer face.
Using some of the left over white fondant, cut some small, thin strips. These are to add some shine to the nose so make them quite small.
Attach your 'shines' to your raindeer nose along with a couple of small balls of black fondant and you have your cute raindeer cup cakes.